Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population.
在非退伍軍人事務部族群中更新和校準糖尿病現實世界進展模型 (RAPIDS)。
Diabetes Obes Metab 2024-09-03
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
將此醫學文章的標題翻譯為繁體中文:「將心血管結果試驗證據納入第2型糖尿病健康經濟建模的挑戰與陷阱」。
Diabetes Obes Metab 2023-03-16
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
發展一個針對2型糖尿病患者的SGLT2和DPP-4抑制劑治療選擇演算法:一項回顧性cohort研究。
Lancet Digit Health 2023-03-22
Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes.
評估葡萄糖降低藥物對第二型糖尿病實際世界患者心血管臨床風險管理的有效性:在模型錯誤和遺漏結果下的目標最大概似估計。
Int J Environ Res Public Health 2023-09-18
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
將 IQVIA 核心糖尿病模型校準至一周一次的 semaglutide 在 SUSTAIN 6 心血管結果試驗中的中風結果。
J Med Econ 2023-11-06
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.
第二型糖尿病患者腎臟疾病進展的風險評估及SGLT2抑制劑的療效。
Diabetes Care 2023-09-25
Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.
SGLT-2抑制劑和GLP-1受體激動劑療效的預測因子:一項回顧性cohort研究。
Diabetes Metab Res Rev 2024-02-19
Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study.
GLP-1激動劑與生活方式指導在肥胖與糖尿病前期管理中的混合方法有效性:RWE回顧性研究。
Metabol Open 2024-05-04
Global Validation of a Model to Predict Reduced Estimated GFR in People With Type 2 Diabetes Without Diagnosis of CKD.
全球驗證一個模型以預測未診斷慢性腎病 (CKD) 的 2 型糖尿病患者的估計 GFR 減少。
Kidney Int Rep 2024-07-31